C21 licensing agreement (treatment for idiopathic pulmonary fibrosis)
A contractual theme involving the in-licensing from Vicore Pharma of exclusive development and commercialization rights in Japan for C21, a treatment for idiopathic pulmonary fibrosis.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.